Last updated: February 13, 2026
Overview
NDC 61442-0141 corresponds to Elexacaftor/Tezacaftor/Ivacaftor (Trikafta), a combination therapy approved by the FDA in October 2019 for cystic fibrosis (CF) in patients aged 6 and older with at least one F508del mutation. It rapidly gained market share due to its superior efficacy compared to earlier CF treatments.
Market Size and Growth Potential
- Estimated global CF population: approximately 70,000 patients, with 40,000 in the U.S. (Cystic Fibrosis Foundation Data [1]).
- U.S. CF patients eligible for Trikafta: estimated at 28,000, considering mutation profiles.
- Market penetration: Rapid uptake since launch, driven by proven efficacy and expanded indications.
Price History and Current Pricing
- List Price (Americas): Approximately $311,000 annually per patient (per CVS Caremark [2]).
- Pricing strategies: Reflects high development costs, rarity, and proven clinical benefit.
- Reimbursements: Manufacturer offers patient assistance programs; insurance coverage is broad, with prior authorization.
Market Dynamics and Competition
- Key competitors: Orkambi (Lumacaftor/Ivacaftor), Symdeko (Tezacaftor/Ivacaftor), and newer pipeline drugs.
- Trikafta’s edge: Higher efficacy, broader mutation coverage, and increased patient adherence.
- Patent status: Patents extend until 2035-2037, securing exclusivity.
Pricing Projections and Future Trends
- Short-term (next 2-3 years): Prices expected to remain stable with potential slight reductions due to volume-based discounts and biosimilar entry in other markets.
- Medium-term (3-5 years): Likely to see minimal price erosion; focus on expanding indications (e.g., younger age groups) might increase overall revenue.
- Long-term: Patent protections shield prices; biosituation in other markets may lower costs through generics or biosimilars, yet U.S. price reductions are limited due to market exclusivity.
Market Forecasts and Revenue Estimates
| Year |
Estimated Market Size (Patients) |
Expected Revenue |
Notes |
| 2023 |
20,000 |
$6.22 billion |
High penetration, limited competition |
| 2024 |
22,000 |
$6.84 billion |
Expansion to new patient groups |
| 2025 |
25,000 |
$7.78 billion |
Market stabilizes, minor discounts |
| 2026+ |
25,000–27,000 |
$7.78–$8.4 billion |
Revenue plateau as market matures |
Pricing Adjustments and Discount Trends
Market pressure may lead to:
- Slight price reductions of 5-10% for broader access.
- Managed entry of biosimilars outside the U.S. could influence global pricing.
- Value-based pricing models are under consideration by insurers, potentially influencing future pricing.
Regulatory and Policy Impact
- Policy discussions around drug pricing and orphan drug incentives could shape future pricing strategies.
- U.S. Medicaid and Medicare might negotiate better discounts due to statutory rebate requirements.
Conclusion
NDC 61442-0141 (Trikafta) commands a high list price stemming from its innovative profile and market exclusivity. Its sales trajectory is driven by expanding indications and increasing patient access, with modest downward pressure expected due to market saturation and potential biosimilar threats in other regions. Nonetheless, the high efficacy profile sustains its premium pricing.
Key Takeaways
- Trikafta's U.S. list price remains around $311,000 annually.
- Market expansion and indication growth support revenue forecasts exceeding $7 billion annually.
- Price erosion considered minimal in the coming years due to patent protection and market exclusivity.
- Competitive pressures might lead to marginal discounts, especially with biosimilar developments outside the U.S.
- Policy and rebate strategies could influence future pricing dynamics.
Frequently Asked Questions
1. How does Trikafta’s price compare globally?
Global pricing varies, often lower outside the U.S. due to different regulatory, reimbursement, and pricing policies.
2. Are there biosimilar options for Trikafta?
No biosimilars are currently approved in the U.S.; biosober developments are underway in other regions, which may influence global prices.
3. What is the likely impact of new CF therapies on Trikafta’s market share?
Emerging treatments with improved efficacy or broader indications could erode market share but are unlikely to fully replace Trikafta soon.
4. How do insurance coverage policies affect Trikafta’s pricing?
Broad coverage with prior authorizations and patient assistance programs facilitates high utilization but may limit net prices through rebates and discounts.
5. What factors could significantly alter future price projections?
Patent expirations, biosimilar approval, policy reforms, and significant clinical trial data could lead to substantial price adjustments.
References
[1] Cystic Fibrosis Foundation. (2022). Cystic Fibrosis Foundation Patient Registry Annual Data Report.
[2] CVS Caremark. (2022). Formularies and drug price transparency reports.
